SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about competition and a prolonged share-price decline. Many expect further weakness, while bulls argue pessimism is already priced in and see room for a rebound if results or the outlook are stronger than feared.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Heavy buying and a sharp rebound have fueled speculation about a potential buyout or imminent company news, but neither has been confirmed. The main catalyst in discussion is the Phase 3 REGAL trials pending final analysis after the last disclosed count of 78 of 80 events; bullish traders read the CEOs optimistic anniversary post as encouraging, while skeptics point to the lack of new trial news and caution that the move may reflect trading activity.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound above recent technical levels has traders discussing a possible breakout and short covering, though no specific new catalyst is confirmed. Bulls are also anticipating DM1 and FSHD siRNA readouts, while some caution that the move may reflect broader biotech strength or prove temporary.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs shares fell despite a third-quarter earnings beat and a new buyback, as traders focused on the narrowed full-year profit outlook and unchanged midpoint. The reaction is split between dip buyers citing cash generation and repurchases, and bears who see the outlook and softer sales as outweighing those positives.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly beat and raised 2026 outlook are being overshadowed by a sharp selloff. Traders debate whether it is a sell-the-news reaction after expectations ran high or a response to rising costs, weaker cash conversion and an insurance loss, while some point to strong orders as evidence demand remains robust.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in bipolar mania met its primary and secondary endpoints, fueling buying interest and analyst optimism. Traders are debating whether the efficacy signal is strong enough given the modest placebo-adjusted improvement, higher discontinuation rates, and safety questions, contributing to volatile trading.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is drawing attention as traders watch for Q3 results to confirm continued growth in high-margin ASCENIV amid weakness in BIVIGAM, with the recent move around its 200-day average adding to the recovery discussion. Bulls point to ASCENIV and share repurchases, while skeptics cite uncertain growth and lingering concerns from the Culper short report and related litigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal

Aspire Biopharma (NASDAQ: ASBP) completes $30M cash acquisition of Dura Driver Control Systems, adding $200M+ in annual revenue.read more...

ASBP Stock Heads For Best Week In Over 2 Months – Why This Drug Delivery Tech Firm Is Buying An Auto Supplier?

Equity

The company announced the acquisition of Dura Driver Control Systems for $30 million in cash.

Healthcare Disruption, AI Biologics, and Wall Street Upgrades Ignite a Midday Market Surge

Healthcare innovators are pushing the markets today. $TGNT, $AGL, $ATRA, $ASBP

ASBP Stock Jumps 21% On Buyback Offer – Retail Believes Every Dip’s A Buying Opportunity

Aspire Biopharma’s board approved a share repurchase program of up to $5 million, which will be funded from existing cash.

ASBP Bulls Back In Control After 78% Crash: What Changed? 

The company closed a $21 million private placement that lifted its shareholders’ equity above Nasdaq’s minimum listing requirement.

LCID, ASBP, WLDS Stocks Hit 52-Week Lows: What Drove The Selloff?

The declines came amid leadership uncertainty, financing concerns, and downward revisions in price targets from Wall Street analysts.

LCID, ABT, ASBP Stocks Hit 52-Week Lows Today: What’s Driving The Selloff?

LCID and ABT each fell about 6% on Thursday, while ASBP plunged 45%, bucking a broader market rally.

ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin –  Retail Expects Licensing Negotiations Soon

The FDA’s feedback supports a planned new drug application submission in the second half of 2026.

Aspire-Lakewood Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company was founded on February 2, 2025 and is headquartered in Estero, FL.

Aspire-Lakewood Holdings Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Aspire Biopharma said it is looking to diversify its revenue streams and boost its earnings and cash flow profile.</li><li>Dura Driver Control Systems is a global automotive supplier with an annual revenue of $200 million.</li><li>It operates 11 manufacturing facilities across North America, Europe, and Asia and holds more than 310 patents.</li></ul>Shares of Aspire Biopharma Holdings (ASBP) drew investor attention on Friday after the company announced an expansion into the automotive sector through the acquisition of Dura Driver Control Systems.<a href="https://stocktwits.com/symbol/ASBP">ASBP stock</a> is heading for its best week in more than two months.<h2 class="st-heading-2">Why Is ASBP Acquiring DCS?</h2>Aspire Biopharma, a firm with patent-pending drug-delivery technology, said it is looking to diversify its revenue streams and boost its earnings and cash flow profile. According to its latest earnings report for the year ended Dec. 31, 2025, Aspire, a pre-revenue company, posted a loss of more than $24 million.Dura Driver Control Systems (DCS), a global automotive supplier of electronic driver control systems for electric vehicles, generates more than $200 million in annual revenue. DCS operates 11 manufacturing facilities across North America, Europe, and Asia and holds more than 310 patents.“Concurrently, this strengthened financial foundation allows us to optimize our proprietary drug delivery technology and advance commercial opportunities for our innovative caffeine product portfolio,” said Kraig Higginson, Interim CEO and Chairperson of the Aspire Biopharma Board.<h2 class="st-heading-2">How Did ASBP Fund The Acquisition?</h2>Aspire will acquire 100% of DCS for $30 million in cash, with the transaction expected to close in the third quarter of 2026.In April, the company <a href="https://stocktwits.com/news-articles/markets/equity/why-asbp-stock-is-surging-after-78-percent-crash/cZBIWpURICk">secured</a> a commitment for a senior secured credit facility of up to $22.5 million to help fund its acquisition. The five-year loan is expected to cover a significant portion of the purchase price. On Monday, the company said it does not plan to raise new equity to complete the deal.<h2 class="st-heading-2">Retail Bullish Despite Early Decline</h2>Retail sentiment on Stocktwits for ASBP turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.On May 11, the company implemented a one-for-thirty reverse share split.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-gmm-stock-is-surging-in-pre-market/cZK5xCeR7Pr">GMM Stock Soared 60% Pre-Market Today – A Look At Some Key Highlights That Got Investors Talking</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kraken Robotics on Tuesday announced that it has entered into an agreement to acquire Covelya Group Limited.(Image Courtesy: Getty Images)

Aspire Biopharma Holdings Inc

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$8.73
Prev Close	$8.41
Open	$8.73
Dividend Yield	0.00%
50-Day Moving Average	$8.38
Beta	1.84
Avg. Volume	37,106.76
PE Ratio	-0.08

52-Week High	$562.92
52-Week Low	$3.31
Market Capitalization	$11.8M
EPS (Annual)	-$491.27
Price to Book	0.93
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

ASBP Fundamentals